Sensitivity and specificity in this case was 68% and 53%, respectively. Impression of atrophy added little to sensitivity and specificity (78% and 64%) over p53 protein structure objective measurement. These data are not. included in the numerical analysis or Figure 2 On observation,

however, these data indicate that the addition of an imaging measurement adds little to an already relatively high sensitivity for clinical assessment, in the case Inhibitors,research,lifescience,medical of AD versus normal controls. Figure 2. Summary of sensitivity and specificity of clinical and imaging modalities. The box plots show the distribution of values in each category by indicating the 10th, 25th, 50th, 75th, and 90th percentiles. Values below 10% or above 90% are depicted as individual … Table III. Sensitivity and specificity of magnetic resonance imaging measures. AD, Alzheimer’s disease; NINCDS, NINCDS (National Institutes of Neurological, Communicative Disorders and Stroke) probable AD (clinical); NINCDS possible,

NINCDS possible or probable … Positron emission tomography Table IV illustrates Inhibitors,research,lifescience,medical Inhibitors,research,lifescience,medical the results of PET studies. The most. notable is the report by Silverman et al,2 which combined results of 284 PET studies, including 138 with histopathologic diagnoses and the others with 2 years’ clinical follow-up. The scans were interpreted by nuclear medicine physicians and classified into profiles. AD was identified (blind to clinical information) with a sensitivity Inhibitors,research,lifescience,medical of 94% and specificity of 73%. Similarly, Hoffman15 qualitatively examined parietotemporal

(PTC) hypometabolism achieving sensitivity and specificity of 93% and 63%, respectively. There were two studies that examined the distinction of AD from dementia with Lewy bodies (DLB).33,33 These studies achieved diagnostic sensitivity of 86% and 92%. The data from these two studies are not. included in the numerical analysis as they represent a fundamentally different measurement than that used in the diagnosis of AD and Inhibitors,research,lifescience,medical more appropriately represent a measurement that distinguishes subjects with DLB. Table IV. Sensitivity and specificity of positron emission tomography measures. AD, Alzheimer’s disease; NINCDS, NINCDS (National Institutes of Neurological, Communicative Disorders and Stroke) probable AD (clinical); CERAD, CERAD (Consortium to Establish a Registiy … Single photon emission computed tomography The widest, variation in diagnostic accuracy overall was apparent in the studies using SPECT. Seven studies reported next a total of 35 measurements; the most, relevant to the diagnosis of AD are included in Table V. ,14,29,34-37 The best, sensitivity/specificity in distinguishing subjects with AD versus normal controls reached 96%/87%,by calculating a discriminant function based on regional cerebral blood flow (rCBF) of multiple brain regions.3“ Impressionistic studies of decreased parietotemporal blood flow achieved a maximal sensitivity/specificity of 89%/80%.